An mHealth Strategy to Improve Medication Adherence in Adolescents with Sickle Cell Disease

NIH RePORTER · NIH · K23 · $168,480 · view on reporter.nih.gov ↗

Abstract

Project Summary (Abstract) Research: Sickle cell disease (SCD) is the most common genetic disorder in the US, affecting about 100,000 Americans, and about 1 in 400 African American live births, incurring annual health care costs of $335 million. SCD complications lead to significant declines in health-related quality of life (HRQOL), culminating in early mortality, particularly among adolescents and young adults (AYA). Hydroxyurea (HU) reduces morbidity and mortality, improves HRQOL and lowers healthcare utilization. Low HU adherence is common and has been associated with worse health outcomes, poor HRQOL and increased healthcare utilization. Our preliminary data suggested that low HU adherence was associated with worse HRQOL scores. However, the longitudinal relationship between HU adherence and HRQOL remains unclear. Our pilot data also suggest that AYA with SCD are interested in using a multi-function SCD-app to facilitate disease self-management and to improve HU adherence, which we were able to develop a prototype for (HU-Go app). The specific aims for Dr. Badawy's research project are to: (1) Determine the longitudinal relationship of HU adherence behavior to health-related quality of life, barriers to adherence and habit formation among AYA with SCD; (2) Refine the design of HU-Go using an iterative user-centered design approach and determine the usability and usefulness of the refined HU- Go app; and (3) Test the feasibility and acceptability of the HU-Go app as an mHealth behavioral intervention to improve HU adherence among AYA with SCD. Candidate: Dr. Badawy is a pediatric hematologist. The support of this career development award will help Dr. Badawy become an independent physician-investigator with the training and experience necessary to improve medication adherence behavior and HRQOL in adolescents with SCD using mHealth behavioral interventions. Dr. Badawy will use this award to build on his existing foundation in health services and outcomes research to develop expertise in: (1) mHealth behavioral interventions research and the application of user-centered design principles; (2) developmental and behavior change theory as it relates to medication adherence with particular focus on AYA; (3) use of mobile technologies for clinical outcomes assessment, including, HRQOL; (4) advanced biostatistics; and (5) behavioral clinical trials for mHealth-based interventions. These skills will enable Dr. Badawy to establish an independent, programmatic line of research and build a transdisciplinary research team to integrate behavioral and technological approaches to improve health outcomes and HRQOL in adolescents with SCD. Dr. Badawy will achieve these career objectives through a 5-year career development plan that involves structured didactics, patient-oriented experiential research, and intensive mentoring. Environment: The exceptional institutional environment will be critical to support Dr. Badawy's career development, including the (1) D...

Key facts

NIH application ID
9870473
Project number
1K23HL150232-01
Recipient
LURIE CHILDREN'S HOSPITAL OF CHICAGO
Principal Investigator
Sherif Mohamed Badawy
Activity code
K23
Funding institute
NIH
Fiscal year
2020
Award amount
$168,480
Award type
1
Project period
2020-03-01 → 2025-02-28